Abstract
The conventional route for drug discovery and development is a costly and time-consuming process. Many initiatives, such as the Critical Path Initiative, have been launched to encourage the use of mathematical, statistical, and computational tools in the drug development and regulatory review process, paving the way for the Model-Informed Drug Discovery and Development pathway. These tools enable the identification of a lead candidate having the right mix of pharmacokinetic, pharmacodynamic, and biopharmaceutical properties with high probability of success.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: From Current to Future Trends in Pharmaceutical Technology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
